Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab Effect on Influenza Vaccine Response in Asthma (VECTOR)
NCT05062759Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in asthma, sponsored by AstraZeneca. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05062759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062759.